Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell Lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study

This study is all about improving how we treat a type of blood cancer called large B-cell lymphoma, especially in patients who are going to have a treatment called CAR T-cell therapy. CAR T-cell therapy is a very clever treatment where some of a patient's own immune cells are specially trained in a lab to find and kill cancer cells. Before this therapy, the study uses a unique type of scan, called an 89Zr-atezolizumab PET/CT scan, to look closely at the cancer cells.

The main idea is to see if we can use this special scan to predict how well CAR T-cell therapy will work for each individual. The scan looks for specific proteins on the cancer cells called PD-L1. By seeing how much of this protein is present and where, researchers hope to understand if higher or lower levels might mean the CAR T-cell therapy is more or less likely to be successful. This could help doctors choose the best treatment path for each patient and give them a better idea of what to expect.

Another important aim of the study is to use this special scan to help tell the difference between active lymphoma and other non-harmful changes that can sometimes show up on regular scans after treatment. Sometimes, after CAR T-cell therapy, scans can show areas of inflammation (swelling) that might look like the cancer has come back, but actually, it's just the body's immune system reacting. This study hopes that the new scan can help doctors tell these apart, so patients don't get unnecessary further treatments or worry about something that isn't the cancer returning.